Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response.
作者信息
Palladini Giovanni, Milani Paolo, Basset Marco, Russo Francesca, Lavatelli Francesca, Nuvolone Mario, Ferraro Giovanni, Bozzola Margherita, Foli Andrea, Perlini Stefano, Merlini Giampaolo
机构信息
a Amyloidosis Research and Treatment Center, Foundation (IRCCS) Policlinico San Matteo , Pavia , Italy and.
b Department of Molecular Medicine , University of Pavia , Pavia , Italy.
出版信息
Amyloid. 2017 Mar;24(sup1):54-55. doi: 10.1080/13506129.2017.1289916.
Abstract
摘要
相似文献
1
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response.心脏功能障碍的严重程度和可逆性以及淀粉样变性轻链的残留浓度可预测获得完全缓解的AL淀粉样变性患者的总生存期。
Amyloid. 2017 Mar;24(sup1):54-55. doi: 10.1080/13506129.2017.1289916.
2
Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio.利用治疗结束时受累游离轻链水平优化AL淀粉样变性的深度缓解评估：血清游离轻链比值的不足
Leukemia. 2019 Feb;33(2):527-531. doi: 10.1038/s41375-018-0258-y. Epub 2018 Sep 26.
3
Outcome of very young (≤40 years) patients with immunoglobulin light chain (AL) amyloidosis.
Amyloid. 2017 Mar;24(sup1):50-51. doi: 10.1080/13506129.2017.1286584.
4
Involved free light chains <10 mg/L with treatment predict better outcomes in systemic light-chain amyloidosis.治疗过程中受累游离轻链<10mg/L预示系统性轻链淀粉样变有更好的预后。
Am J Hematol. 2021 Jan;96(1):E20-E23. doi: 10.1002/ajh.26025. Epub 2020 Nov 5.
5
Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type.淀粉样变性伴轻链型（AL）淀粉样变患者诊断时的免疫球蛋白缺乏状态因治疗方案类型而异，影响治疗反应和生存。
Amyloid. 2017 Mar;24(sup1):44-45. doi: 10.1080/13506129.2017.1281117.
6
Systemic Amyloidosis due to Monoclonal Immunoglobulins: Cardiac Involvement.由于单克隆免疫球蛋白引起的系统性淀粉样变性：心脏受累。
Hematol Oncol Clin North Am. 2020 Dec;34(6):1055-1068. doi: 10.1016/j.hoc.2020.07.006. Epub 2020 Sep 14.
7
Clinical presentation and prognosis of light-chain amyloidosis patients with unmeasurable free light-chain levels.无法检测到游离轻链水平的轻链淀粉样变性患者的临床表现和预后。
Ann Hematol. 2018 Dec;97(12):2465-2470. doi: 10.1007/s00277-018-3460-0. Epub 2018 Jul 28.
8
Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis.多参数流式细胞术检测到微小残留阴性对 AL 淀粉样变性患者生存的影响。
Amyloid. 2020 Mar;27(1):13-16. doi: 10.1080/13506129.2019.1666709. Epub 2019 Sep 23.
9
Outcome of Cardiac Light-Chain Amyloidosis in the Era of Novel Therapy - A Single-Center Cohort Study of 227 Patients.新型治疗时代心脏轻链淀粉样变的转归 - 227 例患者的单中心队列研究。
Circ J. 2019 Mar 25;83(4):775-782. doi: 10.1253/circj.CJ-18-1048. Epub 2019 Feb 16.
10
Revisiting complete response in light chain amyloidosis.重新审视轻链淀粉样变性中的完全缓解。
Leukemia. 2020 May;34(5):1472-1475. doi: 10.1038/s41375-019-0664-9. Epub 2019 Nov 26.
引用本文的文献
1
Role of the mechanisms for antibody repertoire diversification in monoclonal light chain deposition disorders: when a friend becomes foe.抗体库多样化机制在单克隆轻链沉积病中的作用：当朋友变成敌人。
Front Immunol. 2023 Jul 13;14:1203425. doi: 10.3389/fimmu.2023.1203425. eCollection 2023.
2
Daratumumab Monotherapy in Severe Patients with AL Amyloidosis and Biopsy-Proven Renal Involvement: A Real Life Experience.达雷妥尤单抗单药治疗重度 AL 淀粉样变性且经活检证实有肾脏受累患者：一项真实病例经验
J Clin Med. 2020 Oct 9;9(10):3232. doi: 10.3390/jcm9103232.
Zotero 插件